PEI (Paul-Ehrlich Institute) selected for WHO blood/IVDs group:
This article was originally published in Clinica
Executive Summary
Germany's federal office for sera and immunology, the Paul-Ehrlich Institute (PEI), has been selected to join the WHO's co-operation centre for quality assurance in blood products and in vitro diagnostics. The Langen-based unit, which took over responsibility for these area from the former BGA in 1994, will support the WHO in lifting standards "to a level that we have long enjoyed in Germany and Europe", said state secretary at the health ministry Dr Klaus Theo Schroder. Head of the PEI's haematology and transfusion medicine division Professor Rainer Seitz will represent the German institute at the co-operation centre for an initial four-year term.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.